European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

MT Newswires Live06-08 23:10

European equities traded in the US as American depositary receipts kicked off the week higher late Monday morning, lifting 0.82% to 1,874.41 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and biotech firm Evaxion (EVAX), which rose 7% and 4.5% respectively. They were followed by accommodations booking company trivago (TRVG) and telecommunications company Nokia (NOK), which increased 4.4% and 1.7% respectively.

The decliners from continental Europe were led by pharmaceutical company Novo Nordisk (NVO) and biopharmaceutical company Cellectis (CLLS), which fell 2.9% and 2.3% respectively. They were followed by pharmaceutical company Sanofi (SNY) and biopharmaceutical company Grifols (GRFS), which were down 2% each.

The gainers from the UK were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and NuCana (NCNA), which advanced 4.5% and 3.3% respectively. They were followed by oil and gas company BP (BP) and biopharmaceutical company Amarin (AMRN), which were up 1.7% and 1.6% respectively.

The decliners from the UK and Ireland were led by biotech company Autolus Therapeutics (AUTL) and biopharmaceutical company Mereo BioPharma Group (MREO), which dropped 4.2% and 2.4% respectively. They were followed by utilities company National Grid (NGG) and pharmaceutical company GSK (GSK), which lost 2% and 1.2% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment